Heart Valve Disease: TAVR Expansion to Lower-Risk and Younger Patients
The TAVR Evolution: From High-Risk to Low-Risk
TAVR for severe aortic stenosis progressed through four risk tiers in landmark trials: PARTNER 1B (inoperable, 2010), PARTNER 1A/CoreValve Extreme Risk (high-risk, 2011-2014), PARTNER 2A/SURTAVI (intermediate-risk, 2016-2017), and PARTNER 3/Evolut Low Risk (low-risk, 2019). In PARTNER 3, TAVR with the SAPIEN 3 valve demonstrated a lower rate of the composite primary endpoint (death, stroke, or rehospitalization) at 1 year: 8.5% versus 15.1% for SAVR (HR 0.54, 95% CI 0.37-0.79, p = 0.001). The Evolut Low Risk trial showed TAVR non-inferiority to surgery for the composite of death or disabling stroke at 24 months (5.3% vs 6.7%).
Durability: The Critical Unknown for Younger Patients
Transcatheter valve durability data remain limited beyond 5-8 years. Five-year data from PARTNER 2A show structural valve deterioration (SVD) in approximately 2-3% of TAVR valves, comparable to surgical bioprosthetic valves at the same timeframe. However, mechanical stress modeling and accelerated wear testing suggest that TAVR valves may have shorter functional lifespans than surgical bioprostheses due to non-circular deployment geometry and residual stress on leaflets. For patients with life expectancy exceeding 10-15 years, this durability uncertainty is the primary argument for continued surgical referral. The 2024 ACC/AHA valvular heart disease guidelines recommend shared decision-making with a heart valve team and emphasize that SAVR remains preferred for patients under age 65 given durability concerns.
Bicuspid Aortic Valve: An Expanding Frontier
Bicuspid aortic valve (BAV), present in approximately 50% of patients with severe AS under age 70, was excluded from pivotal low-risk trials. BAV anatomy presents technical challenges: asymmetric calcification, larger annular dimensions, and higher rates of paravalvular leak. Retrospective registries and the BAVARD study suggest contemporary TAVR in BAV achieves acceptable outcomes in experienced centers, with procedural success exceeding 95% using newer-generation self-expanding and balloon-expandable valves. However, concomitant aortopathy requiring surgical intervention (ascending aortic diameter above 4.5 cm) remains a contraindication to isolated TAVR.
Sponsored
Transcatheter Mitral and Tricuspid Interventions
The COAPT trial demonstrated that transcatheter edge-to-edge repair (MitraClip) reduced heart failure hospitalizations by 47% and all-cause mortality by 38% in patients with severe secondary mitral regurgitation despite optimized GDMT. Patient selection is critical: the COAPT eligibility criteria (effective regurgitant orifice area above 0.3 cm2, LVEDV below 200 mL, LVEF 20-50%) define a disproportionate MR population that benefits. For tricuspid regurgitation, the TriClip (TRILUMINATE Pivotal) demonstrated superiority over medical therapy for TR reduction, though mortality and heart failure hospitalization benefits at 1 year did not reach significance. The transcatheter tricuspid field remains earlier in development compared to aortic and mitral interventions.
Lifetime Management and the Heart Valve Team
For patients with severe AS, the initial valve intervention decision must consider the entire lifetime trajectory. A 50-year-old patient may require 2-3 valve interventions over their lifetime, making the sequence of procedures critical. Valve-in-valve TAVR for degenerated surgical bioprostheses achieves excellent outcomes when the original surgical valve is 23 mm or larger, but small surgical valves (19-21 mm) risk patient-prosthesis mismatch with TAV-in-SAV. This lifetime planning, weighing initial TAVR convenience against potential future limitations, underscores the importance of multidisciplinary heart valve team assessment for all patients, particularly those under 75.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.